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ABSTRACT Angiotensin II (AII), acting via its G-protein
linked receptor, is an important regulator ofcardiac, vascular,
and renal function. Following injection of All into rats, we
find that there is also a rapid tyrosine phosphorylation of the
major insulin receptor substrates 1 and 2 (IRS-1 and IRS-2)
in the heart. This phenomenon appears to involve JAK2
tyrosine kinase, which associates with the ATI receptor and
IRS-1/IRS-2 after AII stimulation. AII-induced phosphory-
lation leads to binding of phosphatidylinositol 3-kinase (PI
3-kinase) to IRS-1 and IRS-2; however, in contrast to other
ligands, AII injection results in an acute inhibition of both
basal and insulin-stimulated PI 3-kinase activity. The latter
occurs without any reduction in insulin receptor or IRS
phosphorylation or in the interaction of the p85 and pllO
subunits of PI 3-kinase with each other or with IRS-1/IRS-2.
These effects ofAII are inhibited by ATI receptor antagonists.
Thus, there is direct cross-talk between insulin and AII
signaling pathways at the level of both tyrosine phosphory-
lation and PI 3-kinase activation. These interactions may play
an important role in the association of insulin resistance,
hypertension, and cardiovascular disease.
Insulin resistance occurs in a wide variety of pathological states
and is a central component of non-insulin dependent diabetes
mellitus (1). The frequent clustering of insulin resistance,
hypertension, central obesity, hypertriglyceridemia, and accel-
erated atherosclerosis has lead to the definition of a common
metabolic condition often referred to as syndrome X (2, 3).
Over the past decade, many of the proteins involved in insulin
action have been defined at a molecular level (4). The insulin
receptor is a protein tyrosine kinase which, when activated by
insulin binding, undergoes rapid autophosphorylation and
phosphorylates intracellular protein substrates, including Shc,
one or more 50-60 kDa proteins, and two related high
molecular weight insulin receptor substrates, IRS-1 and IRS-2
(4, 5). Following tyrosine phosphorylation, IRS-1 and IRS-2
act as docking proteins for several Src homology 2 domain-
containing molecules, including phosphatidylinositol 3-kinase
(PI 3-kinase), Grb2, SHPTP2, NCK, and Fyn (4, 6, 7). The
interaction between the IRS proteins and PI 3-kinase occurs
through the p85 regulatory subunit of the enzyme and results
in an increase in catalytic activity of the pllO subunit (6, 8). PI
3-kinase is essential for many insulin-sensitive metabolic pro-
cesses including stimulation of glucose transport, activation of
the p70 S6 and Akt serine kinases, and stimulation of glycogen
and protein synthesis (9-13).
Angiotensin II (AII) plays an important role in cardiovas-
cular and neuroendocrine physiology and fluid volume ho-
meostasis, and may also act as a growth factor for heart and
vascular smooth muscle (14). Angiotensin-converting enzyme
inhibitors are a cornerstone in the therapy of human hyper-
tension and cardiac failure (15). Most of the known actions of
AII are exerted through the AT1 receptor, a G-protein-
coupled receptor, which is linked to the stimulation of phos-
pholipase C (16). In addition, All stimulation results in
activation of mitogen-activated protein kinase (17), and, as we
and others have recently shown, stimulation of tyrosine phos-
phorylation of several proteins such as IRS-1 (18), Shc (14),
paxillin (19), and the STAT transcription factors (20), which
are normally involved in the action of various growth factors,
including insulin. In view of the important association between
insulin resistance, hypertension, and cardiovascular disease, in
this study we have explored the interaction between the insulin
and angiotensin signaling systems in the intact rat and found
both positive and negative cross-talk between these two hor-
monal response pathways.
MATERIALS AND METHODS
Antibodies and Chemicals. Antibodies against IRS-1, IRS-2,
and the insulin receptor were prepared as described (5, 21).
Polyclonal antibodies against JAK2, AT1 receptor, and the pllOa
catalytic subunit of PI 3-kinase were from Santa Cruz Biotech-
nology. Monoclonal antibodies against phosphotyrosine (4G10)
and polyclonal antibodies against the p85 regulatory subunit of PI
3-kinase were from Upstate Biotechnology. Affinity-purified
rabbit anti-mouse IgG was from Dako. [125I]protein-A and
[32P]ATP were from Amersham and NEN/DuPont, respectively.
Protein A-Sepharose 6MB was from Pharmacia. Rat liver phos-
phatidylinositol was from Avanti Polar Lipids. All other reagent
grade chemicals were from Sigma.
Animals. Male Wistar rats (180-200 g) were allowed free
access to standard rodent chow and water ad libitum. Food was
withdrawn 12 hr before the experiments. Rats were anesthe-
tized by intraperitoneal injection of sodium amobarbital (100
mg/kg body wt), and the experiments were performed after
the loss of corneal and pedal reflexes.
All and Insulin Treatment and Tissue Preparation. In vivo
stimulation of the heart was obtained by injection of 200-,ul
solutions containing either AII, insulin, or saline into the
inferior vena cava. The tip of the left ventricle was excised after
60 sec and immediately homogenized (Polytron PTA 20S
generator, Brinkmann) in freshly prepared 50 mM Hepes
buffer (pH 7.4) containing 137 mM NaCl, 1 mM MgCl2, 1 mM
CaCl2, 2 mM Na3VO4, 10mM sodium pyrophosphate, 100mM
sodium fluoride, 2 mM EDTA, 2 mM phenylmethylsulfonyl
flouride, 10 ,ug/ml aprotinin, 10 ,ug/ml leupeptin, 10 mM
benzamidine, 10% (vol/vol) glycerol, and 1% (vol/vol) Non-
idet P-40; insoluble material was removed by centrifugation for
45 min at 15,000 rpm in a 70.Ti rotor (Beckman) at 4°C. The
protein concentration of the supernatants was determined by
the Bradford method (45).
PI 3-Kinase Assay. Aliquots of supernatants containing
equal amounts of proteins were incubated overnight at 4°C
Abbreviations: AII, angiotensin II; IR, insulin receptor; IRS-1 and
IRS-2, insulin receptor substrates 1 and 2; PI 3-kinase, phosphatidyl-
inositol 3-kinase.
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using antibodies against IRS-1, IRS-2, or the p85 subunit of PI
3-kinase, and the immunocomplexes were precipitated with a
50% solution of protein A-Sepharose 6MB. In vitro PI 3-kinase
assays were performed as described (6). The 32P-labeled
3-P-phosphatidylinositol was quantitated by the IMAGEQUANT
software of the Phosphorlmager (Molecular Dynamics).
Immunoprecipitations and Western Blotting. Tyrosine phos-
phoproteins and other specific proteins were detected by immu-
noprecipitation followed by SDS/PAGE and Western blotting as
described (6, 21). An amplification step with rabbit anti-mouse
IgG (1:1000 final dilution) was added to the standard protocol
when 4G10 monoclonal anti-phosphotyrosine antibodies were
employed in Western blotting experiments.
Statistics. For comparison of data presented as mean
SEM, the paired Student's t test was used.
RESULTS
Effects of AII and Insulin on Tyrosine Phosphorylation,
JAK Kinase, and PI 3-Kinase Docking. To explore the inter-
actions between the insulin and AII signaling pathways in vivo,
rats were injected with insulin and/or All and the early steps
in signal transduction were assessed using extracts of heart, a
tissue which responds to both hormones. Immunoprecipitation
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FIG. 1. IRS-1 or IRS-2 phosphorylation and PI 3-kinase binding in
rat heart after saline (C), insulin (I), or AII (AII) treatment. Rats were
injected with saline or 200 ,ul of 10-6 M insulin or 10-8 M angiotensin.
Tissues were extracted and immunoblots prepared as described. (A and
B) Nitrocellulose transfers blotted with anti-phosphotyrosine antibody
and the tyrosine phosphorylated band corresponding to IRS-1 (A) and
IRS-2 (B). The nitrocellulose transfers were stripped and reblotted
with antibodies to the p85 (C and D) and piiOa subunits (E and F) of
PI 3-kinase. The bar graphs show the relative phosphorylation of IRS-1
and IRS-2 and the binding of p85 and pllOa as determined by
PhosphorImager quantitation. Data are presented as mean ± SEM.
Stimulation was significant (P < 0.05) as determined using a paired
Student's t test (n = 5).
of extracts with anti-IRS-1 or anti-IRS-2 antisera, followed by
immunoblotting with anti-phosphotyrosine antibodies, re-
vealed a rapid phosphorylation of IRS-1 and IRS-2 following
injection of either insulin or AII (Fig. 1A and B). The increase
in phosphorylation was accompanied by an association of both
IRS-1 and IRS-2 with the enzyme PI 3-kinase as determined
by immunoblotting of the complex with antibodies to either the
regulatory (p85) or catalytic (p11O) subunits of the protein
(Fig. 1 C-F). Quantitation of multiple experiments revealed
that All increased the tyrosyl phosphorylation of IRS-1 and
IRS-2 by 2.6- and 3.8-fold, respectively, and increased the
association of these proteins with the p85 regulatory and pi iOa
catalytic subunits of PI 3-kinase by about 3- to 4-fold. Under
the same conditions, insulin induced a 6- to 8-fold increase in
the tyrosine phosphorylation of IRS-1 and IRS-2 and a parallel
increase in their association with PI 3-kinase.
In addition to insulin and IGF-1, which act via tyrosine
kinase receptors, several cytokines, interferons, and growth
hormones also stimulate phosphorylation of IRS-1 and IRS-2
through receptors that lack intrinsic kinase activity, but appear
to recruit cytoplasmic tyrosine kinases of the Janus kinase
(JAK) family (5, 22, 23). Recent studies suggest that AII can
also stimulate JAK2 kinase (20). To determine the role ofJAK
kinases in tyrosine phosphorylation of IRS-1/IRS-2, we per-
formed immunoprecipitation of cardiac muscle extracts using
anti-JAK2 antibody and immunoblotting with anti-phospho-
tyrosine antibody. After AII or insulin stimulation, the anti-
JAK2 immunoprecipitates contained phosphotyrosyl proteins
of -180 and 130 kDa not observed in the saline-treated controls
(Fig. 2A). Reprobing of the filters with specific antibodies indi-
cated that the -180-kDa protein corresponds to IRS-1 and
AL [P: AntI-JAK2Blot: AnI-pY
B. [P: Anti-IRS-1[lot: AntI-JAK2
C. IP: Anti-IRS-2
Blot: Ant1oJAK-2
D IP: Anti-AT1 R
Blt: Ani-pY
E. [iP: Anti-ATI R
[lot: AntIJAK-2
C I All
_ - 180 kDa
_ -- 130 kDa
_- JAK2
- JAK2
-4--- 130kDa
--_ JAK2
FIG. 2. Autoradiograms ofSDS/PAGE ofJAK2 immunoprecipitates
from rat heart after saline (C), 10-5 M insulin (I), or 10-8 All (AII)
treatment. The animals were treated as described in Fig. 1, except that the
extracts were precipitated with anti-JAK2 antibody. The nitrocellulose
filters were then blotted with anti-phosphotyrosine antibody, followed by
rabbit anti-mouse IgG (1:1000, final dilution) and 125I-protein-A. The
bands appearing at 180 and 130 kDa were confirmed to be IRS-1/IRS-2
and JAK2 by stripping the filter and reblotting with anti-IRS-1, anti-
IRS-2, and anti-JAK2 antibodies. In parallel complementary experi-
ments, the extracts were immunoprecipitated with anti-IRS-1 (B) or
anti-IRS-2 (C), run out on SDS gels, transferred to nitrocellulose, and
blotted with the anti-JAK2 antibody. (D and E) Immunoprecipitation
with anti-AT1 receptor antibody followed by blotting with anti-
phosphotyrosine and anti-JAK2 antibodies.
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IRS-2, whereas the 130-kDa protein corresponds to JAK2 (not
shown). Direct immunoprecipitation with anti-IRS-1 or anti-
IRS-2 antisera followed by blotting with anti-JAK2 antiserum
confirmed the association of IRS-1 and IRS-2 with JAK2 fol-
lowing AII or insulin treatment (Fig. 2 B and C). Likewise,
immunoprecipitation of rat heart extracts using anti-AT1 recep-
tor antibody followed by blotting with anti-JAK2 antibody re-
vealed that JAK2 co-precipitated with the AT1 receptor, and that
tyrosine phosphorylation of JAK2 in the AT1 receptor immu-
noprecipitates was stimulated by AII (Fig. 2 D and E).
Inhibition ofPI 3-Kinase by AII. Numerous previous studies
using insulin, IGF-1, and other ligands have shown that
following binding of p85 to phosphorylated IRS-1 or IRS-2,
the catalytic activity of PI 3-kinase is stimulated several-fold (5,
6, 8). Similarly, following insulin injection into rats, there were
4.2-fold (P < 0.05) and 8-fold (P < 0.005) increases in IRS-1-
and IRS-2-associated PI 3-kinase activity in cardiac muscle
(Fig. 3). Surprisingly, however, following AII injection there
was a dose-dependent inhibition of PI 3-kinase activity asso-
ciated with IRS-1 and IRS-2, with maximal decreases of 55%
(P < 0.05) and 60% (P < 0.01) below basal values after
injection of as little as 200 pmol of AII (Fig. 3).
The ability of All to inhibit PI 3-kinase activity was also
observed during insulin stimulation (Fig. 4). When AII (10-8
M) was infused 1 min before insulin, the levels of IRS-1- and
IRS-2-associated PI 3-kinase activity were reduced by 74%
(P < 0.01) and 86% (P < 0.005), respectively, as compared
with insulin treatment alone. Inhibition was also observed with
simultaneous administration of both insulin and All, although
the effect was slightly smaller (data not shown). Infusion of a
peptide blocker of the AT1 receptor 1 min before All treat-
ment completely prevented All-induced IRS-1 phosphoryla-
tion (data not shown), as well as the inhibitory effect of All on
insulin stimulated, IRS-1-associated PI 3-kinase activity, but
had no effect on basal or insulin-stimulated PI 3-kinase activity
(Fig. 4 B and C). This is in agreement with our previous
observation that DUP 753 (Losartan), a non-peptidal blocker
of the AT1 receptor, also leads to a reduction in the All-
induced tyrosine phosphorylation of the IRS-1 (18). The
ability of AII to inhibit insulin-stimulated PI 3-kinase activity
occurred without any effect of All to alter insulin stimulation
of insulin receptor or IRS-1/IRS-2 phosphorylation and with
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no significant reduction in the binding of p85 to IRS-1/IRS-2
or pllO to p85 (Fig. 5).
DISCUSSION
Intracellular interactions between different signaling systems
may function as mechanisms of enhancement or counter-
regulation of hormone action. Recent evidence indicates that
ligands signaling through G-protein-coupled receptors may
mimic some effects classically observed after activation of
tyrosine kinase receptors, including activation of mitogen-
activated protein kinase, PI 3-kinase, ppi25FAK, JAK2, and
phosphotyrosine phosphatases (17, 20, 24). This study dem-
onstrates that in the case of All, the cross-talk with typical
tyrosine kinase-mediated pathways are multiple and result in
direct interactions between.the All and insulin signaling
systems. AII is able to induce the rapid tyrosine phosphory-
lation of IRS-1 and IRS-2 in rat heart in a physiologic
dose-responsive manner. This phosphorylation probably oc-
curs in the cardiac myocytes themselves, because immunocy-
tochemical experiments reveal that these cells are major sites
of expression for IRS-1 (F.F. and C.R.K., unpublished obser-
vation) and angiotensin receptors (25) in heart. This phos-
phorylation event appears to be mediated by JAK2, which
undergoes rapid phosphorylation following AII stimulation
and associates with the AII receptor and IRS-1/IRS-2 (ref. 20
and this study). Insulin (Fig. 2B and C), growth hormone (26),
and interleukins (23) also stimulate JAK2 phosphorylation
and association with tyrosyl phosphorylated IRS-1 and IRS-2.
Thus, the association between JAK2 and IRS-1/IRS-2 appears
to be common to phosphorylation stimulated by several ty-
rosine kinases, as well as non-tyrosine kinase receptors, al-
though it is not clear whether this interaction is direct or if this
complex involves some other molecule(s).
It is interesting to note that the AT1 receptor possesses an
NPXXY motif that is required for many of its actions (16, 27).
This motif is reminiscent of the NPXY motif present in the
insulin and interleukin 4 receptors, which is required for IRS-1
phosphorylation and downstream signaling and, in the insulin
receptor, is phosphorylated in response to hormonal stimula-
tion (28, 29). Following All stimulation, the AT1 receptor
undergoes both serine and tyrosine phosphorylation (30),
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FIG. 3. IRS-1- and IRS-2-associated PI 3-kinase activity in rat heart after saline (C), insulin (I), and AII treatment. Rats were injected with
hormones as described, and the hearts extracted and immunoprecipitated overnight using antibodies against IRS-1 or IRS-2. PI 3-kinase assays
were performed as described (6). Fluorographs show the silica TLC plates of IRS-1- (Left) and IRS-2- (Right) associated PI 3-kinase activity. PI
3-P indicates the migration position of phosphatidylinositol 3-phosphate. Bar graphs depict the relative incorporation of 32p into PI 3-P (mean ±
SEM) from five separate experiments. The inhibition by 10-10 and 10-8 M AII was significant at P s 0.05, in comparison with saline-injected
controls. The inhibition at 10-6 M AII was significant at P < 0.01.
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FIG. 4. Effect of insulin and AII on PI 3-kinase activity and the role
of AT1 receptor. Animals were injected with AII or insulin alone, or
sequentially with AII and then insulin 1 min later. Tissues were
extracted and assayed as described. (A and B) Fluorographs of silica
TLC plates of IRS-1-associated PI 3-kinase activity in rat heart after
saline (C), 10-5 M insulin (I), 10-8 M AII (AII), or 10-8 M or AT1
receptor peptide inhibitor (QGVYVHPV, Sigma) treatment.
(AII + I) Animals that received 10-8M AII 1 min before the injection
of 10-5 M insulin. The bar graph in C depicts the relative incorporation
of 32p in PI 3-P (mean ± SEM) of four separate experiments, the
reversal of the All effect by the receptor. Inhibitor was significant at
the P < 0.05 level.
although no data are available at present as to whether this
occurs at the NPXXY site. Nonetheless, it is tempting to
hypothesize that phosphorylation of the AT1 receptor at the
NPXXY motif might be necessary for JAK2/IRS1-2/PI 3-ki-
nase mediated signaling.
In all cases in which there is stimulation of tyrosine phos-
phorylation of IRS-1 and IRS-2, there is a concomitant
docking of these proteins to the p85 subunit of PI 3-kinase. In
all previous cases, this docking was associated with a stimu-
lation of the PI 3-kinase enzyme activity. What was surprising
in this study, however, is that IRS-1- and IRS-2-associated PI
3-kinase activity is inhibited following All injection rather
than stimulated. This effect is direct in that it occurs acutely,
and both IRS-1 and IRS-2 phosphorylation and the inhibition
of PI 3-kinase activity can be blocked by inhibitors of the AT1
receptor (see ref. 18 and this study). This inhibitory phenom-
enon is also observed in liver (data not shown).
Interactions between G-protein-coupled receptors and ty-
rosine kinase signaling pathways have been previously re-
ported. Tyrosyl phosphorylation of the 32-adrenergic receptor
by insulin has been shown to produce supersensitization of
adrenergic signaling (31), whereas protein kinase A activation
leads to attenuation of insulin- and epidermal growth factor-
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FIG. 5. Lack of effect of All on insulin-stimulated receptor and
IRS-i phosphorylation and p85 binding. (A and B) Anti-phosphoty-
rosine immunoblots of anti-insulin receptor (IR) and anti-IRS-i
immunoprecipitates from rat hearts after saline (C), i0-5 M insulin
(I), 10-8 AII (All), or treatment with a sequential infusion of AII and
insulin with a 60-sec interval between each infusion. (A and B) Bands
appearing at 95 kDa and 165-185 kDa are shown as IR and IRS-1,
respectively. (C) Lower part of the nitrocellulose transfer from the
anti-IRS-1 preciptitates was blotted with anti-p85 antibody. (D) Data
of six replicate experiments has been quantitated by PhosphorImager
analysis and are shown as mean + SEM. None of the differences in
insulin-receptor phosphorylation, IRS-1 phosphorylation, or p85 bind-
ing to IRS-1, are statistically significant between the insulin alone
group and the insulin plus All group.
stimulated mitogen-activated protein kinase activity (32). In-
sulin receptors are capable of tyrosine phosphorylating G1, Go,
and transducin in vitro (33, 34), andwe and others have previously
shown that insulin is able to inhibit ADP ribosylation of G1 (35,
36). Gia2 deficiency in liver and adipose tissue of transgenic mice
has also been shown to result in impaired glucose tolerance and
insulin resistance associated with attenuated insulin-stimulated
tyrosine phosphorylation of IRS-1 (37).
Our studies show a new and more direct level of interaction
between receptor tyrosine kinases and receptors acting
through G-proteins with phosphorylation of a substrate of the
insulin receptor following AII stimulation (see ref. 18 and this
study). More importantly, in this study we find the first
evidence of a reduction of PI 3-kinase activity after its
association with a tyrosyl-phosphorylated docking protein.
The precise mechanism of this inhibition is unknown. It is not
due to a dissociation of the p85 and pllO subunits of PI
3-kinase. Other possibilities would include differential sites of
tyrosyl phosphorylation on IRS-1 and IRS-2 proteins following
All and insulin treatment, recruitment of an inhibitor of PI-3
kinase activity to the IRS-1 complex by All, or some covalent
modification of p85 or pllO that alters enzymatic activity. Of
these possibilities, the latter seems most likely since it has been
A.
B.
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shown in vitro that phosphorylation of p85 on Ser-608 reduces
the catalytic activity of PI 3-kinase (38). Furthermore, using rat
aortic smooth muscle cells in culture, we find that All inhi-
bition of PI 3-kinase activity is associated with a 50% increase
in the serine phosphorylation of the p85 regulatory subunit.
This phenomenon is also observed following phorbol 12-
myristate 13-acetate stimulation suggesting a possible role for
protein kinase C in the inhibitory effect of All- on IRS-
associated PI 3-kinase activity (F.F., C.R.K., and E. P. Feener,
unpublished work). In adipocytes, insulin-stimulated PI 3-ki-
nase activation is crucial for glucose transport, cell growth,
protein synthesis, and stimulation of the 70-kDa S6 kinase (9,
10, 13). In heart, despite the inhibition of PI 3-kinase activity,
All stimulates cellular hypertrophy and growth acting through
both the mitogen-activated protein kinase and 70-kDa S6
kinase pathways (39). Thus, cross-talk between All and insulin
signaling must take place at several levels.
The implications of intracellular interactions between the
All and insulin signaling systems are many. It seems likely that
this interaction is physiologically important, because it occurs
at physiological concentrations of hormone in intact animals
and because one of the most common disease associations in
humans is between diabetes, insulin resistance, and hyperten-
sion. Furthermore, both insulin and angiotensin have effects
on cardiac and vascular smooth muscle growth and hypertro-
phy, and the insulin resistance/hypertension syndrome is
associated with accelerated atherosclerosis (2, 3, 14). Admin-
istration of angiotensin-converting enzyme inhibitors and AT1
receptor blockers to both normal and hypertensive individuals
has also been shown to result in improved insulin sensitivity
and even hypoglycemia, strongly suggesting an association
between elements involved in glucose homeostasis control and
blood pressure (40-42). Recent evidence also suggests that
insulin-mediated vasodilation contributes to increased insulin
sensitivity and responsiveness in human skeletal muscle (43).
Thus, part of the insulin "sensitizing" effect of angiotensin-
converting enzyme inhibitors might be ascribed to vasodila-
tion, especially in the face of the increased vascular tone,
typical of hypertension. Furthermore, in hyperinsulinemic
clamp studies, although All infusion results in decreased
glucose extraction across the leg, this is more than compen-
sated for by the increase in blood flow to the same tissue (44).
In summary, intracellular cross-talk between All and insulin
signaling may be of pathophysiologic significance in the insulin
resistance associated with hypertension and accelerated ath-
erosclerosis. The potential for this interaction as a site for new
therapeutic approaches of insulin resistance, as well as for
increased understanding of the insulin signaling and G-protein
mediated pathways, deserves further exploration.
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